Dr. Reddy's Laboratories Limited (BOM:500124)
India · Delayed Price · Currency is INR 1,264.80
+19.15 (1.54%)
At close: Oct 10, 2025
Dr. Reddy's Laboratories Revenue
Dr. Reddy's Laboratories had revenue of 85.45B INR in the quarter ending June 30, 2025, with 11.37% growth. This brings the company's revenue in the last twelve months to 334.26B, up 15.86% year-over-year. In the fiscal year ending March 31, 2025, Dr. Reddy's Laboratories had annual revenue of 325.54B with 16.61% growth.
Revenue (ttm)
334.26B
Revenue Growth
+15.86%
P/S Ratio
3.10
Revenue / Employee
12.02M
Employees
27,811
Market Cap
1,036.88B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 325.54B | 46.37B | 16.61% |
| Mar 31, 2024 | 279.16B | 33.29B | 13.54% |
| Mar 31, 2023 | 245.88B | 31.49B | 14.69% |
| Mar 31, 2022 | 214.39B | 24.67B | 13.00% |
| Mar 31, 2021 | 189.72B | 15.12B | 8.66% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Reliance Industries | 9,765.41B |
| HDFC Bank | 2,736.06B |
| Bharti Airtel | 1,839.41B |
| Tata Consultancy Services | 2,561.48B |
| ICICI Bank | 2,054.85B |
| State Bank of India | 3,503.84B |
| Bajaj Finance | 387.76B |
| Infosys | 1,672.76B |
Dr. Reddy's Laboratories News
- 1 day ago - Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs - Benzinga
- 3 days ago - My Top 5 Biotech Stocks Big Pharma Could Buy Next - Seeking Alpha
- 4 days ago - Bullish Two Hundred Day Moving Average Cross - RDY - Nasdaq
- 4 days ago - ESPR Settles Nexletol/Nexlizet Patent Litigation With RDY, Stock Up - Nasdaq
- 6 days ago - Esperion Therapeutics (ESPR) Settles Patent Dispute with Dr. Reddy's - GuruFocus
- 7 days ago - Esperion settles patent dispute with Dr. Reddy’s over cholesterol drugs - Seeking Alpha
- 7 days ago - Dr. Reddy's (RDY) Reaches Settlement in Patent Dispute with Esperion - GuruFocus
- 11 days ago - Nifty 50 top losers today, September 29: Axis Bank, Maruti Suzuki, Dr. Reddy’s Laboratories, Adani Enterprises, HDFC Life and more - Business Upturn